Primary mediastinal large B-cell lymphoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:98838C85.2
Who is this for?
Show terms as
1FDA treatments10Active trials34Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
May 2026Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy

Fondazione Italiana Linfomi - ETS

TrialNOT YET RECRUITING
Nov 2024Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

Sun Yat-sen University — PHASE2

TrialRECRUITING
Oct 2024CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

University of Maryland, Baltimore — PHASE1

TrialENROLLING BY INVITATION
Sep 2024Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma

St. Petersburg State Pavlov Medical University — PHASE1, PHASE2

TrialENROLLING BY INVITATION
Jun 2024Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Allogene Therapeutics — PHASE2

TrialRECRUITING
Jun 2024A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Sun Yat-sen University — PHASE2

TrialNOT YET RECRUITING
Feb 2023Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Memorial Sloan Kettering Cancer Center — PHASE1

TrialACTIVE NOT RECRUITING
Jan 2023ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Acepodia Biotech, Inc. — PHASE1

TrialRECRUITING
Jun 2022Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

IRCCS San Raffaele

TrialACTIVE NOT RECRUITING
Apr 2022Bio-CAR-T BS Study

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Breyanzi

lisocabtagene maraleucel· Juno Therapeutics, Inc.■ Boxed Warning
adult patients with large B-cell lymphoma (LBCL), including primary mediastinal large B-cell lymphoma, who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first

adult patients with large B-cell lymphoma (LBCL), including primary mediastinal large B-cell lymphoma, who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or relapsed or refractory disease after 2 or more lines of systemic therapy

Clinical Trials

10 recruitingView all trials with filters →
Phase 31 trial
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Phase 3
Active
PI: Lisa G Roth (Children's Oncology Group) · Sites: Birmingham, Alabama; Mobile, Alabama +231 more · Age: 299 yrs
Phase 22 trials
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
Phase 2
Actively Recruiting
PI: Ranjit Nair (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 1899 yrs
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Phase 2
Actively Recruiting
PI: Allogene Study Director (Allogene Therapeutics, Inc.) · Sites: Gilbert, Arizona; Hot Springs, Arkansas +59 more · Age: 1899 yrs
Phase 13 trials
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
Phase 1
Active
PI: Jae Park, MD (Memorial Sloan Kettering Cancer Center) · Sites: New York, New York · Age: 1899 yrs
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Phase 1
Actively Recruiting
· Sites: Orlando, Florida; Atlanta, Georgia +11 more · Age: 1899 yrs
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Phase 1
Enrolling by Invitation
PI: Djordje Atanackovic, MD (Professor of Medicine) · Sites: Baltimore, Maryland · Age: 1899 yrs
N/A1 trial
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
N/A
Actively Recruiting
PI: VINCENT CAMUS, MD (Centre Henri Becquerel) · Sites: Lyon; Rouen · Age: 1899 yrs
Other3 trials
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
Active
· Sites: Milan, Italy · Age: 1880 yrs
Bio-CAR-T BS Study
Actively Recruiting
· Sites: Brescia · Age: 1870 yrs
Italian Observational Study on CAR-T Therapy for Lymphoma
Actively Recruiting
· Sites: Milan · Age: 1899 yrs

Specialists

Showing 25 of 34View all specialists →
MM
Matthew Frigault, MD
Boston, Massachusetts
Specialist

Rare Disease Specialist

PI on 2 active trials
AD
Amrita Desai
Specialist
PI on 1 active trial
CM
Chirayu Patel, MD
BOSTON, MA
Specialist
PI on 1 active trial
MM
Mitchell Cairo, MD
HAWTHORNE, NY
Specialist
PI on 11 active trials
MP
Mengyang Di, MD, PhD
SEATTLE, WA
Specialist
PI on 2 active trials
FD
François-Xavier GROS, Prof. Dr.
Specialist
PI on 1 active trial
FM
Frederick Locke, MD
TAMPA, FL
Specialist
PI on 1 active trial
CD
Catherine THIEBLEMONT, Prof. Dr.
Specialist
PI on 1 active trial
GD
Gabriel BRISOU, Prof. Dr.
Specialist
PI on 1 active trial
TM
Thomas E. Witzig, MD
ROCHESTER, MN
Specialist
PI on 9 active trials
SM
Sarah Larson, MD
Specialist
PI on 1 active trial
PM
Pytlik Robert, M.D.
Specialist
PI on 1 active trial
NM
Nathan Denlinger, DO, MS
COLUMBUS, OH
Specialist
PI on 1 active trial
MP
Marek Trněný, M.D., PhD.
Specialist
PI on 1 active trial
KM
Kevin Hay, MD
EL PASO, TX
Specialist
PI on 1 active trial
AH
Alexandre Hirayama
Specialist
PI on 1 active trial8 Primary mediastinal large B-cell lymphoma publications
VP
Veronika Bachanova, MD, PhD
MINNEAPOLIS, MN
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Breyanzi(lisocabtagene maraleucel)Juno Therapeutics, Inc.

Travel Grants

No travel grants are currently matched to Primary mediastinal large B-cell lymphoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Primary mediastinal large B-cell lymphomaForum →

No community posts yet. Be the first to share your experience with Primary mediastinal large B-cell lymphoma.

Start the conversation →

Latest news about Primary mediastinal large B-cell lymphoma

Disease timeline:

New recruiting trial: Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

A new clinical trial is recruiting patients for Primary mediastinal large B-cell lymphoma

New recruiting trial: Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

A new clinical trial is recruiting patients for Primary mediastinal large B-cell lymphoma

New recruiting trial: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

A new clinical trial is recruiting patients for Primary mediastinal large B-cell lymphoma

New recruiting trial: Italian Observational Study on CAR-T Therapy for Lymphoma

A new clinical trial is recruiting patients for Primary mediastinal large B-cell lymphoma

New recruiting trial: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

A new clinical trial is recruiting patients for Primary mediastinal large B-cell lymphoma

New recruiting trial: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

A new clinical trial is recruiting patients for Primary mediastinal large B-cell lymphoma

New recruiting trial: Bio-CAR-T BS Study

A new clinical trial is recruiting patients for Primary mediastinal large B-cell lymphoma

New recruiting trial: PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

A new clinical trial is recruiting patients for Primary mediastinal large B-cell lymphoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Primary mediastinal large B-cell lymphoma

Are there clinical trials for Primary mediastinal large B-cell lymphoma?

Yes — 10 recruiting clinical trials are currently listed for Primary mediastinal large B-cell lymphoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Primary mediastinal large B-cell lymphoma?

25 specialists and care centers treating Primary mediastinal large B-cell lymphoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.